Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/109006
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Molecular characterization of carbamoyl-phosphate synthetase (CPS1) deficiency using human recombinant CPS1 as a key tool |
Autor: | Díez-Fernández, Carmen CSIC; Martínez, Ana I.; Pekkala, Satu; Barcelona, Belén CSIC ORCID; Pérez-Arellano, Isabel CSIC | Palabras clave: | Urea cycle CPS1 deficiency Hyperammonemia Carbamylglutamate |
Fecha de publicación: | 28-may-2013 | Editor: | Wiley-Liss | Citación: | Human Mutation;34(8):1149-59. (2013 Aug) | Resumen: | The urea cycle disease carbamoyl-phosphate synthetase deficiency (CPS1D) has been associated with many mutations in the CPS1 gene [Häberle et al., 2011. Hum Mutat 32:579-589]. The disease-causing potential of most of these mutations is unclear. To test the mutations effects, we have developed a system for recombinant expression, mutagenesis, and purification of human carbamoyl-phosphate synthetase 1 (CPS1), a very large, complex, and fastidious enzyme. The kinetic and molecular properties of recombinant CPS1 are essentially the same as for natural human CPS1. Glycerol partially replaces the essential activator N-acetyl-l-glutamate (NAG), opening possibilities for treating CPS1D due to NAG site defects. The value of our expression system for elucidating the effects of mutations is demonstrated with eight clinical CPS1 mutations. Five of these mutations decreased enzyme stability, two mutations drastically hampered catalysis, and one vastly impaired NAG activation. In contrast, the polymorphisms p.Thr344Ala and p.Gly1376Ser had no detectable effects. Site-limited proteolysis proved the correctness of the working model for the human CPS1 domain architecture generally used for rationalizing the mutations effects. NAG and its analogue and orphan drug N-carbamoyl-l-glutamate, protected human CPS1 against proteolytic and thermal inactivation in the presence of MgATP, raising hopes of treating CPS1D by chemical chaperoning with N-carbamoyl-l-glutamate | Descripción: | 11 páginas, 5 figuras, 1 tabla. El fichero contiene el material suplementario. | Versión del editor: | http://dx.doi.org/10.1002/humu.22349 | URI: | http://hdl.handle.net/10261/109006 | DOI: | 10.1002/humu.22349 | ISSN: | 1059-7794 | E-ISSN: | 1098-1004 |
Aparece en las colecciones: | (IBV) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
HumMut_CD.pdf | 1,07 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
19
checked on 13-abr-2024
SCOPUSTM
Citations
33
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
32
checked on 24-feb-2024
Page view(s)
583
checked on 18-abr-2024
Download(s)
668
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.